TLR-4 inhibition of host anti-tumor activity is also controversial, because, if it is true that tumor progression involves TLR-4-mediated production of pro-inflammatory and immunosuppressive cytokines, TLR-4 antagonists reduce pro-inflammatory response, but also compromise host immunity [164]. Here, TLR4 is linked to neoplasm.